Highlights Lyell Immunopharma, Inc.

Equities

LYEL

US55083R1041

Real-time Estimate Cboe BZX Other stock markets 12:00:55 2024-06-05 pm EDT			5-day change	1st Jan Change
2.54 ^USD	+2.01%		-0.39%	+31.44%

May. 06	Sector Update: Health Care Stocks Higher in Late Afternoon Trading	MT
May. 06	Lyell Immunopharma Shares Rise After Q1 Net Loss Narrows	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Sector Update: Health Care Stocks Higher in Late Afternoon Trading	May. 06	MT
Lyell Immunopharma Shares Rise After Q1 Net Loss Narrows	May. 06	MT
Earnings Flash (LYEL) LYELL IMMUNOPHARMA Reports Q1 Revenue $3,000	May. 06	MT
Lyell Immunopharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 06	CI
North American Morning Briefing : Stock Futures -2-	Mar. 04	DJ
Lyell Immunopharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 28	CI
Earnings Flash (LYEL) LYELL IMMUNOPHARMA Reports Q4 Revenue $13,000	Feb. 28	MT
Lyell Immunopharma, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 28	CI
Phoenix Biotech Acquisition Corp. completed the acquisition of CERo Therapeutics, Inc.	Feb. 13	CI
MaxCyte's strategic platform licences redeem otherwise modest results	Jan. 09	AN
Earnings Flash (LYEL) LYELL IMMUNOPHARMA Posts Q3 Revenue $25,000	Nov. 07	MT
Lyell Immunopharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 07	CI
Lyell Immunopharma, Inc. Presents New Nonclinical Data at 38th Annual Meeting of SITC on Innovations Designed to Shorten Tumor Infiltrating Lymphocyte Manufacturing, LYL119 as Well as Data on New Technologies and Design of its Two Clinical Trials in Progress	23-10-31	CI
Cellares and Lyell to Evaluate Automated Manufacturing of Lyell's Car T-Cell Therapy on Cellares' Cell Shuttle Platform	23-09-11	CI
Earnings Flash (LYEL) LYELL IMMUNOPHARMA Reports Q2 Revenue $27,000	23-08-08	MT
Lyell Immunopharma, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-08	CI
MaxCyte inks strategic platform license with Lyell Immunopharma	23-07-06	AN
Phoenix Biotech Acquisition Corp. executed the letter of intent to acquire CERo Therapeutics, Inc. for $86.9 million.	23-06-04	CI
Earnings Flash (LYEL) LYELL IMMUNOPHARMA Reports Q1 Revenue $65,000	23-05-04	MT
LYELL IMMUNOPHARMA, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)	23-05-04	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Lyell Immunopharma, Inc.

Equities

LYEL

US55083R1041

Highlights

Filters